Adeno-associated virus-mediated delivery of a mutant endostatin suppresses ovarian carcinoma growth in mice

I. V. Subramanian, R. Ghebre, Sundaram Ramakrishnan

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

Earlier studies have shown that a point mutation in human endostatin at position 125 (human endostatin wherein proline 125 was substituted with alanine, P125A-endostatin) improves endothelial cell binding and antiangiogenic activity. In the present study, we investigated the effect of recombinant adeno-associated virus (rAAV)-mediated gene delivery of P125A-endostatin (rAAV-P125Aendo) in a mouse model of ovarian carcinoma. Intramuscular (i.m.) injection of rAAV-P125Aendo resulted in a dose-dependent increase in serum endostatin levels. Consequently, vascular endothelial growth factor- and basic fibroblast growth factor-mediated angiogenesis was significantly inhibited in mice injected with rAAV-P125Aendo as compared to control mice injected with rAAV-LacZ. Furthermore, gene therapy using rAAV-P125Aendo construct showed sustained secretion of P125A-endostatin for up to 9 weeks after a single i.m. administration. Recombinant AAV-P125Aendo injection significantly inhibited the growth of human ovarian cancer cells in athymic nude mice. Immunofluorescence studies of residual tumors surgically removed from the rAAV-P125Aendo-treated animals showed decreased number of vessel ends and vessel length, indicating inhibition of angiogenesis. These studies suggest that recombinant AAV-mediated antiangiogenic gene therapy methods can be used to inhibit ovarian cancer growth.

Original languageEnglish (US)
Pages (from-to)30-38
Number of pages9
JournalGene Therapy
Volume12
Issue number1
DOIs
StatePublished - Jan 1 2005
Externally publishedYes

Fingerprint

Endostatins
Dependovirus
Carcinoma
Growth
Nude Mice
Genetic Therapy
Ovarian Neoplasms
Intramuscular Injections
Residual Neoplasm
Fibroblast Growth Factor 2
Point Mutation
Proline
Alanine
Vascular Endothelial Growth Factor A
Fluorescent Antibody Technique
Endothelial Cells
Injections
Serum
Genes

Keywords

  • Angiogenesis
  • Endostatin
  • Mouse model
  • Ovarian cancer
  • rAAV

ASJC Scopus subject areas

  • Genetics

Cite this

Adeno-associated virus-mediated delivery of a mutant endostatin suppresses ovarian carcinoma growth in mice. / Subramanian, I. V.; Ghebre, R.; Ramakrishnan, Sundaram.

In: Gene Therapy, Vol. 12, No. 1, 01.01.2005, p. 30-38.

Research output: Contribution to journalArticle

@article{2e60933b44f0442aa299c46008c508e2,
title = "Adeno-associated virus-mediated delivery of a mutant endostatin suppresses ovarian carcinoma growth in mice",
abstract = "Earlier studies have shown that a point mutation in human endostatin at position 125 (human endostatin wherein proline 125 was substituted with alanine, P125A-endostatin) improves endothelial cell binding and antiangiogenic activity. In the present study, we investigated the effect of recombinant adeno-associated virus (rAAV)-mediated gene delivery of P125A-endostatin (rAAV-P125Aendo) in a mouse model of ovarian carcinoma. Intramuscular (i.m.) injection of rAAV-P125Aendo resulted in a dose-dependent increase in serum endostatin levels. Consequently, vascular endothelial growth factor- and basic fibroblast growth factor-mediated angiogenesis was significantly inhibited in mice injected with rAAV-P125Aendo as compared to control mice injected with rAAV-LacZ. Furthermore, gene therapy using rAAV-P125Aendo construct showed sustained secretion of P125A-endostatin for up to 9 weeks after a single i.m. administration. Recombinant AAV-P125Aendo injection significantly inhibited the growth of human ovarian cancer cells in athymic nude mice. Immunofluorescence studies of residual tumors surgically removed from the rAAV-P125Aendo-treated animals showed decreased number of vessel ends and vessel length, indicating inhibition of angiogenesis. These studies suggest that recombinant AAV-mediated antiangiogenic gene therapy methods can be used to inhibit ovarian cancer growth.",
keywords = "Angiogenesis, Endostatin, Mouse model, Ovarian cancer, rAAV",
author = "Subramanian, {I. V.} and R. Ghebre and Sundaram Ramakrishnan",
year = "2005",
month = "1",
day = "1",
doi = "10.1038/sj.gt.3302352",
language = "English (US)",
volume = "12",
pages = "30--38",
journal = "Gene Therapy",
issn = "0969-7128",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Adeno-associated virus-mediated delivery of a mutant endostatin suppresses ovarian carcinoma growth in mice

AU - Subramanian, I. V.

AU - Ghebre, R.

AU - Ramakrishnan, Sundaram

PY - 2005/1/1

Y1 - 2005/1/1

N2 - Earlier studies have shown that a point mutation in human endostatin at position 125 (human endostatin wherein proline 125 was substituted with alanine, P125A-endostatin) improves endothelial cell binding and antiangiogenic activity. In the present study, we investigated the effect of recombinant adeno-associated virus (rAAV)-mediated gene delivery of P125A-endostatin (rAAV-P125Aendo) in a mouse model of ovarian carcinoma. Intramuscular (i.m.) injection of rAAV-P125Aendo resulted in a dose-dependent increase in serum endostatin levels. Consequently, vascular endothelial growth factor- and basic fibroblast growth factor-mediated angiogenesis was significantly inhibited in mice injected with rAAV-P125Aendo as compared to control mice injected with rAAV-LacZ. Furthermore, gene therapy using rAAV-P125Aendo construct showed sustained secretion of P125A-endostatin for up to 9 weeks after a single i.m. administration. Recombinant AAV-P125Aendo injection significantly inhibited the growth of human ovarian cancer cells in athymic nude mice. Immunofluorescence studies of residual tumors surgically removed from the rAAV-P125Aendo-treated animals showed decreased number of vessel ends and vessel length, indicating inhibition of angiogenesis. These studies suggest that recombinant AAV-mediated antiangiogenic gene therapy methods can be used to inhibit ovarian cancer growth.

AB - Earlier studies have shown that a point mutation in human endostatin at position 125 (human endostatin wherein proline 125 was substituted with alanine, P125A-endostatin) improves endothelial cell binding and antiangiogenic activity. In the present study, we investigated the effect of recombinant adeno-associated virus (rAAV)-mediated gene delivery of P125A-endostatin (rAAV-P125Aendo) in a mouse model of ovarian carcinoma. Intramuscular (i.m.) injection of rAAV-P125Aendo resulted in a dose-dependent increase in serum endostatin levels. Consequently, vascular endothelial growth factor- and basic fibroblast growth factor-mediated angiogenesis was significantly inhibited in mice injected with rAAV-P125Aendo as compared to control mice injected with rAAV-LacZ. Furthermore, gene therapy using rAAV-P125Aendo construct showed sustained secretion of P125A-endostatin for up to 9 weeks after a single i.m. administration. Recombinant AAV-P125Aendo injection significantly inhibited the growth of human ovarian cancer cells in athymic nude mice. Immunofluorescence studies of residual tumors surgically removed from the rAAV-P125Aendo-treated animals showed decreased number of vessel ends and vessel length, indicating inhibition of angiogenesis. These studies suggest that recombinant AAV-mediated antiangiogenic gene therapy methods can be used to inhibit ovarian cancer growth.

KW - Angiogenesis

KW - Endostatin

KW - Mouse model

KW - Ovarian cancer

KW - rAAV

UR - http://www.scopus.com/inward/record.url?scp=11844275275&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=11844275275&partnerID=8YFLogxK

U2 - 10.1038/sj.gt.3302352

DO - 10.1038/sj.gt.3302352

M3 - Article

C2 - 15550927

AN - SCOPUS:11844275275

VL - 12

SP - 30

EP - 38

JO - Gene Therapy

JF - Gene Therapy

SN - 0969-7128

IS - 1

ER -